Orchestra BioMed Holdings, Inc. (OBIO)
| Market Cap | 228.23M |
| Revenue (ttm) | 33.48M |
| Net Income (ttm) | -52.96M |
| Shares Out | 58.52M |
| EPS (ttm) | -1.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 175,798 |
| Open | 4.090 |
| Previous Close | 4.100 |
| Day's Range | 3.850 - 4.090 |
| 52-Week Range | 2.200 - 5.424 |
| Beta | 0.60 |
| Analysts | Strong Buy |
| Price Target | 14.25 (+265.39%) |
| Earnings Date | May 11, 2026 |
About OBIO
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a b... [Read more]
Financial Performance
In 2025, Orchestra BioMed Holdings's revenue was $33.48 million, an increase of 1169.22% compared to the previous year's $2.64 million. Losses were -$52.96 million, -13.22% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 265.39% from the latest price.
News
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Two pivotal cardiovascular programs are advancing, with Virtue DEB offering a novel sirolimus-based delivery and AVIM therapy showing strong enrollment and immediate blood pressure benefits. Strategic partnerships have secured funding and minimized dilution, with AVIM commercialization targeted for 2028.
Orchestra BioMed Holdings Transcript: TD Cowen 46th Annual Health Care Conference
Two pivotal trials are underway for AVIM therapy and Virtue SAB, targeting large hypertension and coronary artery disease markets. Strong partnerships with Medtronic and Terumo, robust clinical data, and a royalty-based model position the company for significant growth, with key milestones expected by 2027.
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
NEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HOPE, Pa., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ho...
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
NEW HOPE, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technolog...
Orchestra BioMed Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference
The company secured $150 million in strategic capital from Medtronic, Ligand, and Terumo, enabling progress on pivotal AVIM and Virtue trials. AVIM targets pacemaker patients with hypertension, with key data expected late next year, while Virtue leverages sirolimus for superior vascular outcomes.
Orchestra BioMed Holdings Transcript: Status Update
Significant capital was raised through strategic partnerships, extending cash runway into late 2027 and supporting pivotal trials for AVIM Therapy and Virtue SAB. Both programs are advancing in large markets, with differentiated technology and strong clinical momentum. Key trial completions and data readouts are targeted for 2026 and 2027.
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed to Host Business Update Call on November 12, 2025
NEW HOPE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements
New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreement Terumo to pay a total of $30 million to Orchestra BioMed Orchestra BioMed ...
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial
NEW HOPE, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit
Presentation to provide comprehensive overview of AVIM Therapy clinical evidence demonstrating the potential to halt the progression of hypertensive heart disease Orchestra BioMed and Medtronic (NYSE:...
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
NEW HOPE, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
NEW HOPE, Pa., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the ...
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
NEW HOPE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
NEW HOPE, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
NEW HOPE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Announces Pricing of $40 Million Public Offering
NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Orchestra BioMed Announces Proposed Public Offering
NEW HOPE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
• Ligand to invest $35 million in exchange for a tiered royalty on future sales of Orchestra's AVIM therapy and Virtue SAB and an additional $5 million in an equity private placement • Medtronic to i...